Korean J Ophthalmol.  2014 Dec;28(6):460-465. 10.3341/kjo.2014.28.6.460.

Elevated Plasma Pentraxin 3 and Its Association with Retinal Vein Occlusion

• Park KS
• Kim JW
• An JH
• Woo JM

• KMID: 2345822
• DOI: http://doi.org/10.3341/kjo.2014.28.6.460

Abstract

PURPOSE
To evaluate plasma pentraxin 3 (PTX3) in patients with retinal vein occlusion (RVO), and investigate the possibility of its role as a predictive biomarker.
METHODS
Nested case-control study. The study included 57 patients with RVO and 45 age- and gender-matched subjects without RVO as controls. Plasma PTX3 and C-reactive protein concentration were measured in both groups a posteriori from frozen samples by using an enzyme-linked immunosorbent assay kit.
RESULTS
The measured PTX3 value for the RVO group was 1,508 +/- 1,183 pg/mL (mean +/- standard deviation) and 833 +/- 422 pg/mL for the controls (p < 0.001). There was no significant difference in PTX3 levels between patients with central retinal vein occlusion and branched retinal vein occlusion (1,468 +/- 1,300 vs. 1,533 +/- 1,121 pg/mL; p = 0.818).
CONCLUSIONS
Our data seems to support the role of chronic inflammation and ischemia in the development of RVO. It is possible that PTX3 can be used as a diagnostic biomarker of RVO.

Keyword

Biological markers; Inflammation; Ischemia; Pentraxin3; Retinal vein occlusion

MeSH Terms

Acute-Phase Proteins/metabolism
Adult
Aged
Aged, 80 and over
Biomarkers/*blood
C-Reactive Protein/*metabolism
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Humans
Male
Middle Aged
Retinal Vein Occlusion/*blood/diagnosis
Serum Amyloid P-Component/*metabolism
Acute-Phase Proteins
Biomarkers
C-Reactive Protein
Serum Amyloid P-Component

Reference

1. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol. 2006; 90:627–639.

2. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50:1025–1032.

3. Jo N, Wu GS, Rao NA. Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003; 44:4054–4060.

4. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105:412–416.

5. Lee HB, Pulido JS, McCannel CA, Buettner H. Role of inflammation in retinal vein occlusion. Can J Ophthalmol. 2007; 42:131–133.

6. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001; 47:403–411.

7. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97:425–428.

8. Goodman AR, Cardozo T, Abagyan R, et al. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev. 1996; 7:191–202.

9. Manfredi AA, Rovere-Querini P, Bottazzi B, et al. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008; 20:538–544.

10. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111:1805–1812.

11. Noma H, Mimura T, Masahara H, Shimada K. Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema. Retina. 2014; 34:352–359.

12. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997; 272:32817–32823.

13. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23:337–366.

14. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006; 17:225–233.

15. Alberti L, Gilardini L, Zulian A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009; 202:455–460.

16. Woo JM, Kwon MY, Shin DY, et al. Human retinal pigment epithelial cells express the long pentraxin PTX3. Mol Vis. 2013; 19:303–310.

17. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21:1876–1890.

18. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010; 11:328–334.

19. Souza DG, Amaral FA, Fagundes CT, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol. 2009; 174:1309–1318.

20. Foteinos G, Xu Q. Immune-mediated mechanisms of endothelial damage in atherosclerosis. Autoimmunity. 2009; 42:627–633.

21. Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002; 22:e10–e14.

22. Yu HI, Sheu WH, Song YM, et al. C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus. Diabet Med. 2004; 21:336–341.

23. Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol. 2011; 58:38–45.

24. Lee DH, Jeon HK, You JH, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J. 2010; 40:370–376.

25. Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29:594–599.

26. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102:636–641.

27. Akerfeldt T, Larsson A. Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures. Inflammation. 2011; 34:367–370.

28. Martin SC, Butcher A, Martin N, et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol. 2002; 86:774–776.

29. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114:1243–1247.

30. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352:29–38.